Sa. Sanjad et al., MANAGEMENT OF HYPERLIPIDEMIA IN CHILDREN WITH REFRACTORY NEPHROTIC SYNDROME - THE EFFECT OF STATIN THERAPY, The Journal of pediatrics, 130(3), 1997, pp. 470-474
The efficacy and safety of hydroxymethylglutaric coenzyme A reductase
inhibitor (statins) in the treatment of hyperlipidemia were evaluated
in 12 infants and children with steroid-resistant nephrotic syndrome f
ollowed prospectively for 1 to 5 years. All patients experienced a hyp
olipidemic response with a marked reduction in their total cholesterol
(40%), low-density lipoprotein cholesterol (44%), and triglyceride le
vels (33%), but no appreciable change in high-density lipoprotein chol
esterol. Statin therapy was well tolerated without clinical or laborat
ory adverse effects. In spite of a significant hypolipidemic response
to statin therapy there were no changes observed in the degree of prot
einuria, hypoalbuminemia, or in the rate of progression to chronic ren
al failure, Long-term controlled studies with statin therapy are neede
d to further document or negate their renoprotective role in refractor
y nephrotic syndrome.